EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors

Immunvermittelte unerwünschte Ereignisse und Überleben bei Patient:innen mit metastasiertem NSCLC unter Immun-Checkpoint-Inhibitoren

Sarah Cook, Vanessa Samuel, Daniel E Meyers, Igor Stukalin, Ishjot Litt, Randeep Sangha, Don G Morris, Daniel Y C Heng, Aliyah Pabani, Michelle Dean, Vishal Navani

JAMA Network Open · 18.01.2024 · 7 (1) · e2352302

DOI: 10.1001/jamanetworkopen.2023.52302 ↗

Auf einen Blick

Bei 803 Patient:innen mit lokal fortgeschrittenem oder metastasiertem NSCLC war das Auftreten klinisch relevanter irAEs mit längerem Gesamtüberleben verbunden. Auch eine Hospitalisierung wegen Toxizität änderte diesen Zusammenhang nicht.

Fragestellung

Wie sind irAEs und ihr Schweregrad bei Patient:innen mit lokal fortgeschrittenem oder metastasiertem NSCLC unter ICIs mit dem Gesamtüberleben assoziiert?

Methode

Retrospektive Beobachtungskohortenstudie mit Daten aus der Alberta Immunotherapy Database; Einschluss von Patient:innen mit NSCLC unter ICIs zwischen 1. März 2014 und 30. November 2021; Follow-up bis 31. März 2023.

Ergebnisse

Unter Ausschluss von Patient:innen mit Überleben <3 Monaten (n = 611) war das mediane OS mit irAEs 23,7 Monate (95 %-KI 19,3-29,1) vs. 9,8 Monate (95 %-KI 8,7-11,4) ohne irAEs; HR 0,53 (95 %-KI 0,40-0,70).

Schlussfolgerung der Autor:innen

Das Auftreten klinisch relevanter irAEs war mit verbessertem Gesamtüberleben verbunden. Der Zusammenhang wurde durch eine Hospitalisierung wegen schwerer Toxizität nicht abgeschwächt; die Wiederaufnahme der ICI-Therapie sollte weiter untersucht werden.

Kernaussagen

  • Klinisch relevante irAEs waren mit längerem OS assoziiert.
  • Medianes OS: 23,7 vs. 9,8 Monate.
  • Hospitalisierung wegen irAE zeigte keinen OS-Unterschied.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JAMA Network Open, online erschienen am 18.01.2024. Verfasst von Sarah Cook und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 183-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Immune-related adverse events (irAEs) secondary to immune checkpoint inhibitor (ICI) therapy reportedly improve overall survival (OS) in patients with non–small cell lung cancer (NSCLC). However, studies have been small and the association between irAE severity and OS remains poorly defined.

Objective

To examine the association between irAEs and their severity with OS in patients with locally advanced or metastatic NSCLC receiving ICIs. Design, Setting, and Participants This retrospective observational cohort study included patients with NSCLC receiving ICIs between March 1, 2014, and November 30, 2021, with follow-up until March 31, 2023. Data analysis was completed April 26, 2023. The Alberta Immunotherapy Database, a provincial, multicenter cohort, was used to capture data from patients receiving ICIs in Alberta, Canada. Participants included 803 patients 18 years or older who received at least 1 cycle of ICI (alone or with chemotherapy), agnostic to treatment line. Exposure Developing an irAE mandating delay or discontinuation of ICI therapy and/or systematic corticosteroids for management of toxic effects (hereinafter referred to as clinically meaningful irAEs). Main Outcomes and Measures The primary outcome was association between irAEs and OS according to Kaplan-Meier analysis. Clinically meaningful irAEs were identified. Patients with poor prognosis (survival &lt;3 months) who may have died prior to irAE development were excluded from OS analysis, mitigating immortal time bias. Adjusted Cox proportional hazards regression analyses ascertained variables associated with OS.

Results

Among the 803 patients included in the analysis, the median age of patients with irAEs was 69.7 (IQR, 63.1-75.2) years and the median age of those without irAEs was 67.5 (IQR, 60.4-73.3) years, with comparable sex distribution (139 of 295 men [47.1%] and 156 of 295 women [52.9%] with irAEs vs 254 of 505 men [50.3%] and 251 of 505 women [49.7%] without irAEs). Mitigating immortal time bias (n = 611), irAEs were associated with OS (median OS with irAEs, 23.7 [95% CI, 19.3-29.1] months; median OS without irAEs, 9.8 [95% CI, 8.7-11.4] months; P &lt; .001). No OS difference was associated with treatment in hospital vs as outpatients for an irAE (median OS, 20.8 [95% CI, 11.7-30.6] vs 25.6 [95% CI, 20.1-29.8] months; P = .33). Developing irAEs remained associated with OS in the total cohort after Cox proportional hazards regression with known prognostic characteristics (hazard ratio, 0.53 [95% CI, 0.40-0.70]; P &lt; .001). Conclusions and Relevance In this cohort study of 803 patients with locally advanced or metastatic NSCLC receiving ICIs, developing a clinically meaningful irAE was associated with improved OS. This association was not compromised by hospitalization for severe toxic effects. Whether and how ICI therapy resumption after an irAE is associated with OS warrants further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAgedFemaleHumansMaleMiddle AgedAlbertaCohort StudiesImmune Checkpoint InhibitorsOutpatientsRetrospective StudiesAdolescentAdult

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, University of Calgary, Calgary, Alberta, Canada.
  • Department of Medical Oncology, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Cross Cancer Institute, Edmonton, Alberta, Canada.
  • Tom Baker Cancer Centre, Calgary, Alberta, Canada.
  • Department of Oncology, Johns Hopkins University, Baltimore, Maryland.

Zitieren

APA

Cook, S., Samuel, V., Meyers, D. E., Stukalin, I., Litt, I., Sangha, R., Morris, D. G., Heng, D. Y. C., Pabani, A., Dean, M., & Navani, V. (2024). Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors. JAMA Network Open, 7(1), e2352302. https://doi.org/10.1001/jamanetworkopen.2023.52302

Vancouver

Cook S, Samuel V, Meyers DE, Stukalin I, Litt I, Sangha R, et al. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors. JAMA Network Open. 2024;7(1):e2352302. doi:10.1001/jamanetworkopen.2023.52302

BibTeX
@article{Cook2024,
  author = {Cook, Sarah and Samuel, Vanessa and Meyers, Daniel E and Stukalin, Igor and Litt, Ishjot and Sangha, Randeep and Morris, Don G and Heng, Daniel Y C and Pabani, Aliyah and Dean, Michelle and Navani, Vishal},
  title = {Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {1},
  pages = {e2352302},
  doi = {10.1001/jamanetworkopen.2023.52302}
}
Kostenlos starten →